Edition:
United States

BioCryst Pharmaceuticals Inc (BCRX.OQ)

BCRX.OQ on NASDAQ Stock Exchange Global Select Market

5.00USD
15 Dec 2017
Change (% chg)

$0.15 (+3.09%)
Prev Close
$4.85
Open
$4.86
Day's High
$5.03
Day's Low
$4.78
Volume
2,522,763
Avg. Vol
381,201
52-wk High
$9.25
52-wk Low
$3.95

Latest Key Developments (Source: Significant Developments)

BioCryst Pharma files for mixed shelf of up to $200 million‍​
Wednesday, 8 Nov 2017 04:45pm EST 

Nov 8 (Reuters) - BioCryst Pharmaceuticals Inc :Files for mixed shelf of up to $200 million - SEC filing‍​.  Full Article

BioCryst Pharmaceuticals reports Q3 loss per share of $0.18
Tuesday, 7 Nov 2017 06:00am EST 

Nov 7 (Reuters) - BioCryst Pharmaceuticals Inc ::Reports third quarter 2017 financial results.Q3 loss per share $0.18.Q3 revenue $8.8 million versus $7.8 million.Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.Q3 revenue view $4.6 million -- Thomson Reuters I/B/E/S.Expect to start single required phase 3 efficacy and long-term safety trials for BCX7353 in Q1 2018 ​.‍U.S. Orphan Drug Designation for BCX7353 received from FDA​.  Full Article

Biocryst’s Rapivab receives FDA approval for a pediatric indication
Thursday, 21 Sep 2017 06:00am EDT 

Sept 21 (Reuters) - Biocryst Pharmaceuticals Inc :Biocryst’s Rapivab (peramivir injection) receives FDA approval for a pediatric indication.Biocryst Pharmaceuticals Inc - ‍FDA has approved a supplemental new drug application for Rapivab​.  Full Article

BioCryst Pharmaceuticals announces underwritten public offering​
Monday, 11 Sep 2017 04:01pm EDT 

Sept 12 (Reuters) - BioCryst Pharmaceuticals Inc :BioCryst Pharmaceuticals Inc - ‍offering to sell $80 million of its common stock in an underwritten public offering​.Biocryst - ‍proceeds to be used for funding global launch preparation of bcx7353, expanding global commercial and manufacturing efforts​.BioCryst Pharmaceuticals Inc - proceeds to be used to support initiation of phase 3 clinical trial for bcx7353, long term safety study.​.  Full Article

Biocryst announces positive results from mid-stage HAE trial
Tuesday, 5 Sep 2017 06:00am EDT 

Sept 5 (Reuters) - Biocryst Pharmaceuticals Inc :Biocryst announces positive results from its Apex-1 Phase 2 trial in HAE.Biocryst Pharmaceuticals Inc - ‍FDA and EMA meetings planned for Q4 2017 to finalize phase​.Biocryst Pharmaceuticals Inc - in Apex Phase 2 trial, ‍73% reduction in overall attack frequency at 125mg dose (p<0.001)​.Biocryst Pharmaceuticals Inc - ‍goal is to start Phase 3 efficacy and long-term safety trials in Q1 of 2018​.Biocryst Pharma- ‍125 mg dose level showed statistically significant,similar benefit for all attacks, also when split into abdominal attacks,peripheral attacks​.Biocryst Pharmaceuticals Inc - ‍intends to meet FDA, EMA during Q4 2017 to finalize Phase 3 program required to support NDA, MAA submissions​.  Full Article

Biocryst Pharmaceuticals Q2 loss per share $0.21
Monday, 7 Aug 2017 06:00am EDT 

Aug 7 (Reuters) - Biocryst Pharmaceuticals Inc :Biocryst reports second quarter 2017 financial results.Q2 loss per share $0.21.Q2 revenue $3.1 million versus $4.8 million.Q2 revenue view $5.8 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.Biocryst Pharmaceuticals - continues to expect 2017 net operating cash use to be $30 million to $50 million, 2017 operating expenses to be $53 million to $73 million​.Biocryst Pharmaceuticals Inc - ‍ after discussions with FDA, NIAID and BARDA, delayed initiation of Galidesivir IV phase 1 clinical trial​.Biocryst - expect next step in Galidesivir's development to be to conduct additional nonclinical efficacy study in delayed treatment setting in ebola disease​.  Full Article

Deerfield Management Co reports 6.81 pct passive stake in Biocryst Pharmaceuticals
Monday, 5 Jun 2017 05:22pm EDT 

June 5 (Reuters) - Biocryst Pharmaceuticals Inc ::Deerfield Management Company, L.p reports a 6.81 percent passive stake in Biocryst Pharmaceuticals Inc as of may 25- sec filing.  Full Article

Biocryst announces Rapivab pediatric SNDA acceptance
Monday, 5 Jun 2017 06:00am EDT 

June 5 (Reuters) - BioCryst Pharmaceuticals Inc -:BioCryst announces rapivab® pediatric snda acceptance.Says snda has been classified by fda as a priority review.Says snda has a pdufa goal date for a decision by end of september 2017.  Full Article

Robert Ingram named chairman of Biocryst Pharmaceuticals
Tuesday, 30 May 2017 07:30am EDT 

May 30 (Reuters) - Biocryst Pharmaceuticals Inc :Robert Ingram named chairman of Biocryst Pharmaceuticals Inc.Biocryst Pharmaceuticals - following company's annual meeting on May 24, 2017, Robert Ingram will serve as chairman of board of directors.George Abercrombie will serve as a member of company's board of directors.  Full Article

BioCryst reports additional positive results from second interim analysis of APEX-1 trial
Thursday, 25 May 2017 08:00am EDT 

May 25 (Reuters) - BioCryst Pharmaceuticals Inc :BioCryst reports additional positive results from the second interim analysis of its APEX-1 trial.BioCryst Pharma - a pre-planned analysis of peripheral and abdominal attacks showed reductions in peripheral attacks of 74%, 54%, 90% compared with placebo.BioCryst Pharmaceuticals Inc says oral BCX7353 once-daily for 28 days was generally safe and well tolerated in subjects with hae.BioCryst Pharmaceuticals Inc says additionally, no significant laboratory abnormalities were observed in two lower dose groups.BioCryst Pharmaceuticals Inc - there were no serious aes and no severe aes in APEX-1 trial.BioCryst Pharmaceuticals - three subjects in bcx7353 350 mg treatment arm, two of which were previously reported, discontinued study drug before day 28.BioCryst Pharmaceuticals Inc says most common treatment-emergent adverse events were common cold and diarrhea in trial.  Full Article

BRIEF-BioCryst Pharma files for mixed shelf of up to $200 million‍​

* Files for mixed shelf of up to $200 million - SEC filing‍​ Source text: (http://bit.ly/2m4wZHE) Further company coverage: